期刊文献+

克罗恩病合并肠瘘273例临床特征与预后分析 被引量:11

Clinical characteristics and prognosisof 273 Crohn'spatientswih gastrointestinal fistulas
原文传递
导出
摘要 目的分析克罗恩病(CD)合并肠瘘病人的临床特征及预后状况。方法回顾性分析2001年1月至2015年6月南京大学医学院附属金陵医院就诊的CD合并肠瘘的273例病人资料,分析其临床特征、肠瘘特点、临床用药方案及预后转归。结果 273例病人中,男女比为2.5:1;起病年龄为29(22,40)岁;确诊年龄为31(25,42)岁;起病至确诊的间隔时间为22(8,31)个月;最常见的首发症状分别为腹痛(78.0%)、腹泻(28.9%)及发热(26.0%);确诊时最常见的发病部位为末端回肠(56.8%);确诊时最常见的发病性质为穿透性病变(54.9%),其次为狭窄(42.1%)、无狭窄无穿孔(2.9%)及肛周病变(19.0%)。共并发肠瘘442例次,其中肠外瘘有327例次(73.9%),最常见的类型为回结肠吻合口瘘124例次(28.1%),肠内瘘有115例次(26.1%),其中肠膀胱瘘38例次(8.6%)。肠内(91.9%)及肠外(72.9%)营养联合柳氮磺胺吡啶(57.9%)及雷公藤多苷(48.0%)是治疗此类病人的最为常用的方法;共有227例(83.1%)病人行抗感染治疗,β-内酰胺类(77.6%)及硝基咪唑类(56.0%)是最常用药物。所有入选病人共接受外科手术625例次,确诊后1、3及5年的累积手术率分别为34.4%、59.0%及63.0%。共有9例(3.3%)病人在随访期间死亡,确诊后1、3、10年的累积存活率分别为98.5%、97.8%和96.7%。结论与西方及其他亚洲国家文献资料相比,该中心CD合并肠瘘病人在性别比、发病部位、手术率及死亡率等方面均存在一定差异,尚须继续进一步随访及深入研究。 ObjectiveTo analyze the clinical characteristics and prognosis of Crohn’s patients with gastrointestinal fistulas.MethodsThe data of 273 patients with gastrointestinal fistulas who were registered in GI Fistula Center,Department of Surgery,Jinling Hospital from January 2001 to June 2015 were retrospectively reviewed and the clinical features,characteristics of gastrointestinal fistulas,medication plan and outcome of the patients were analyzed.ResultsThe ratio of male to female was 2.5:1.The mean onset age was 29(22,40)years.The mean diagnosis age was 31(25,42)years.The averageage between onset to diagnosis was22(8,31)months.The most common initial symptoms were abdominal pain(78.0%),diarrhea(28.9%)and fever(26.0%).The most common lesion locations were terminal ileum(56.8%).The most common behavior of disease were penetrating(54.9%),followed by stricturing(42.1%),inflammatory(2.9%)and perianal disease(19.0%).442 patients developed GI,including intestinal cutaneous fistulas(73.9%)and intestinal fistulas(26.1%).The most type of intestinal cutaneousfistulas were ileocecal anastomotic fistula.The most type of intestinal fistulas were entero-vesical fistulas.Enteral nutrition(91.9%)and parenteralnutrition(72.9%)combined with sulfasalazine(57.9%)and tripterygium glycosides(48.0%)were the most commonly used drugs.A total of 227(83.1%)patientsreceived antibiotics due to infectious complications.Β-lactam(77.6%)and nitroimidazoles(56.0%)were the most common antibi-otics.All the patients had received 625 cases of operations.The cumulative operative rates of 1 year,3 years and 5 years after diagnosis were 34.4%,59.0%and 63.0%.9(3.3%)patients died during the research.The cumulative survival rates were 98.5%,97.8%,and 96.7%at 1 year,3 years and 10 years after diagnosis.ConclusionCompared with the literature of western and other Asian countries,there are some differences in sex ratio,lesion locations,operative rates and mortality ratesamong Crohn’s disease patients with GI fistula.Further followup and in-depth study are needed.
作者 洪之武 任建安 刘颂 王革非 顾国胜 吴秀文 任华建 李原 黎介寿 HONG Zhi-wu;REN Jian-an;LIU Song(Departmentof General Surgery,Jinling Hospital,Medical School of Nanjing University,Nanjing 210002,China)
出处 《中国实用外科杂志》 CSCD 北大核心 2019年第5期492-496,共5页 Chinese Journal of Practical Surgery
基金 国家自然科学基金(No.81571881) 江苏省重点研发计划-社会发展-重点病种规范化诊疗项目(No.BE2016752)
关键词 克罗恩病 肠瘘 炎症性肠病 预后 Crohn's disease gastrointestinal fistula inflammatory bowel disease prognosis
  • 相关文献

参考文献2

二级参考文献25

  • 1毛瑶,任建安,黎介寿.克罗恩病并发肠瘘的病理机制探讨[J].中国实用外科杂志,2006,26(2):108-110. 被引量:1
  • 2Carter M J, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 Suppl 5:V1-16.
  • 3Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI, WestAB Ⅱ. Intestinal subepithelial myofibroblasts. Am J Physiol1999; 277(2 Pt 1): C183-201.
  • 4McKaig BC, McWilliams D, Watson SA, Mahida YR. Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 2003; 162: 1355-60.
  • 5Kruidenier L, Macdonald TT, Collins JE, Pender SLF, Sanderson IR. Myofibroblast matrix metalloproteinases activate the neutrophil chemoattractant CXCL7 from intestinal epithelial cells.Gastroenterology 2006; 130:127-36
  • 6Salmela MT, MacDonald TT, Black D, Irvine B, Zhuma T,Saarialho-Kere U, et al. Upregulation of matrix metalloproteinases in a model of T cell mediated tissue injury in the gut:analysis by gene array and in situ hybridization. Gut 2002; 51:540-7.
  • 7Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J Pathol 2003; 199: 28-35.
  • 8Qiu D, Zhao G, Aoki Y, Shi L, Uyei A, Nazarian S, et al. Immunosuppressant PG490 (triptolide) inhibits T-cell interleukin-2expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappaB transcriptional activation. J Biol Chem 1999; 274:13 443-50.
  • 9Krakauer T, Chen X, Howard OM, Young HA. Triptolide attenuates endotoxin- and staphylococcal exotoxin-induced T-cell proliferation and production of cytokines and chemokines. Immunopharmacol Immunotoxicol 2005; 27: 53-66.
  • 10Yang Y, Liu Z, Tolosa E, Yang J, Li L. Triptolide induces apoptotic death of T lymphocyte. Immunopharmacology 1998; 40: 139-49.

共引文献21

同被引文献104

引证文献11

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部